RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $847
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has maintained a 'Sector Perform' rating on Regeneron Pharmaceuticals (NASDAQ:REGN) and raised the price target from $833 to $847.
October 12, 2023 | 4:53 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals' price target has been raised by RBC Capital from $833 to $847, while maintaining a 'Sector Perform' rating.
The raised price target indicates that the analyst sees potential for the stock's price to increase. This could lead to positive sentiment among investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100